Drug Profile
Atevirdine
Alternative Names: Atevirdine mesylate; U 85961; U 87201; U 87201ELatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Pharmacia Corporation
- Class Antiretrovirals; Piperazines
- Mechanism of Action RNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
- 19 Feb 1999 A study (ACTG 187) has been added to the pharmacokinetics, therapeutic trials, antimicrobial activities and adverse events section
- 11 Apr 1995 Two studies have been added to the pharmacokinetics section ,